{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:26:04Z","timestamp":1794579964761,"version":"4.9.1"},"reference-count":113,"publisher":"Bentham Science Publishers Ltd.","issue":"10","funder":[{"DOI":"10.13039\/501100001868","name":"National Science and Technology Council, Taiwan","doi-asserted-by":"publisher","award":["111-2314-B-006-103-MY2"],"award-info":[{"award-number":["111-2314-B-006-103-MY2"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital, Tainan, Taiwan","doi-asserted-by":"publisher","award":["NCKUH-11201005"],"award-info":[{"award-number":["NCKUH-11201005"]}],"id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Glutamate is implicated in playing a crucial role in modulating the complex\npathophysiological mechanisms of migraines, including central or peripheral sensitization, cortical\nspreading depression, and pain transmission. With expanding knowledge over the last three decades,\nglutamate receptors have become focal points in neurological drug research. Altered plasma glutamate\nlevels during migraines suggest a potential avenue for effective therapies targeting glutamate reduction.\nFurthermore, glutamate is believed to play a vital role in modulating the complex pathophysiological\nmechanisms underlying migraines.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This study aims to provide an overview of the ionotropic glutamate receptor antagonists\n(NMDA, AMPA, and Kainate receptors) and metabotropic glutamate receptors in the context of migraines.\nWe explore the advantages and disadvantages of these receptor modulators as alternative\ntreatments, considering efficacy, tolerability, and safety.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We conducted comprehensive online searches across various electronic databases, with a\nprimary focus on PubMed and clinicaltrials.gov, to gather the latest treatment approaches and emerging\nconcepts.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>A total of 371 articles were identified from PubMed, along with 69 articles from clinicaltrials.\ngov. After refinement, 113 articles were included. We summarize seven different medications currently\nin clinical practice for migraines and highlight six items for migraine therapy in preclinical trials\nand their potential value.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>It's crucial to note that these agents pose certain challenges in specific drug research due\nto their intricate influence and mechanisms of action within multiple neuronal pathways. Therefore,\nfurther studies are warranted to elucidate more specific glutamatergic signaling pathways for migraine\ntherapy while minimizing interference with normal neuronal functions.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x23666250403124115","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T06:59:46Z","timestamp":1744009186000},"page":"1264-1275","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Potential Role of Glutamate Receptors and their Antagonists or Modulators in Migraine Therapy"],"prefix":"10.2174","volume":"23","author":[{"given":"Chih-Hung","family":"Tsai","sequence":"first","affiliation":[{"name":"Department of Neurology, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chi","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of\nPediatrics, Chi-Mei Medical Center, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Cheng Kung Univesity\nHospital, College of Medicine, National Chen Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"6261","DOI":"10.2174\/0929867325666180530114534","volume":"26","author":"V\u00e9csei L.","year":"2019","unstructured":"V\u00e9csei L.; Luk\u00e1cs M.; Tajti J.; F\u00fcl\u00f6p F.; Toldi J.; Edvinsson L.; The therapeutic impact of new migraine discoveries. Curr Med Chem  2019,26(34),6261-6281","journal-title":"Curr Med Chem"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s13311-018-0616-5","volume":"15","author":"Hoffmann J.","year":"2018","unstructured":"Hoffmann J.; Charles A.; Glutamate and its receptors as therapeutic targets for migraine. Neurotherapeutics  2018,15(2),361-370","journal-title":"Neurotherapeutics"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s40265-014-0262-0","volume":"74","author":"Chan K.","year":"2014","unstructured":"Chan K.; MaassenVanDenBrink A.; Glutamate receptor antagonists in the management of migraine. Drugs  2014,74(11),1165-1176","journal-title":"Drugs"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ncl.2019.07.008","volume":"37","author":"Goadsby P.J.","year":"2019","unstructured":"Goadsby P.J.; Holland P.R.; Pathophysiology of Migraine. Neurol Clin  2019,37(4),651-671","journal-title":"Neurol Clin"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jns.2016.06.016","volume":"367","author":"Gasparini C.F.","year":"2016","unstructured":"Gasparini C.F.; Smith R.A.; Griffiths L.R.; Genetic insights into migraine and glutamate: A protagonist driving the headache. J Neurol Sci  2016,367,258-268","journal-title":"J Neurol Sci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/jcbfm.1992.32","volume":"12","author":"Lauritzen M.","year":"1992","unstructured":"Lauritzen M.; Hansen A.J.; The effect of glutamate receptor blockade on anoxic depolarization and cortical spreading depression. J Cereb Blood Flow Metab  1992,12(2),223-229","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"Ashina M.","year":"2020","unstructured":"Ashina M.; Migraine. N Engl J Med  2020,383(19),1866-1876","journal-title":"N Engl J Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/17425255.2019.1578749","volume":"15","author":"Lupi C.","year":"2019","unstructured":"Lupi C.; Benemei S.; Guerzoni S.; Pellesi L.; Negro A.; Pharmacokinetics and pharmacodynamics of new acute treatments for migraine. Expert Opin Drug Metab Toxicol  2019,15(3),189-198","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.pneurobio.2015.12.005","volume":"152","author":"Schytz H.W.","year":"2017","unstructured":"Schytz H.W.; Hargreaves R.; Ashina M.; Challenges in developing drugs for primary headaches. Prog Neurobiol  2017,152,70-88","journal-title":"Prog Neurobiol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10072-012-1058-1","volume":"33","author":"Barbanti P.","year":"2012","unstructured":"Barbanti P.; Aurilia C.; Egeo G.; Fofi L.; Future trends in drugs for migraine prophylaxis. Neurol Sci  2012,33(S1),137-140","journal-title":"Neurol Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1517\/17425255.2014.963554","volume":"10","author":"Tajti J.","year":"2014","unstructured":"Tajti J.; Cs\u00e1ti A.; V\u00e9csei L.; Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors. Expert Opin Drug Metab Toxicol  2014,10(11),1509-1520","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"Aurora S.K.","year":"2010","unstructured":"Aurora S.K.; Dodick D.W.; Turkel C.C.; DeGryse R.E.; Silberstein S.D.; Lipton R.B.; Diener H.C.; Brin M.F.; PREEMPT 1 Chronic Migraine Study Group. Onabotulinumtoxin A for treatment of chronic migraine: Results from the double-blind; randomized.; placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia  2010,30(7),793-803","journal-title":"Cephalalgia"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"Diener H.C.","year":"2010","unstructured":"Diener H.C.; Dodick D.W.; Aurora S.K.; Turkel C.C.; DeGryse R.E.; Lipton R.B.; Silberstein S.D.; Brin M.F.; PREEMPT 2 Chronic Migraine Study Group. Onabotulinumtoxin A for treatment of chronic migraine: Results from the double-blind.; randomized.; placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia  2010,30(7),804-814","journal-title":"Cephalalgia"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1468-2982.2008.01749.x","volume":"29","author":"Ferrari A.","year":"2009","unstructured":"Ferrari A.; Spaccalopelo L.; Pinetti D.; Tacchi R.; Bertolini A.; Effective prophylactic treatments of migraine lower plasma glutamate levels. Cephalalgia  2009,29(4),423-429","journal-title":"Cephalalgia"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1526-4610.2007.00812.x","volume":"47","author":"Vieira D.S.","year":"2007","unstructured":"Vieira D.S.; Naffah-Mazzacoratti M.G.; Zukerman E.; Soares C.A.S.; Cavalheiro E.A.; Peres M.F.P.; Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine. Headache  2007,47(6),842-847","journal-title":"Headache"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2174\/187152707781387279","volume":"6","author":"Michail Vikelis","year":"2007","unstructured":"Michail Vikelis ; Mitsikostas D.D.; The role of glutamate and its receptors in migraine. CNS Neurol Disord Drug Targets  2007,6(4),251-257","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1017\/S1092852900018757","volume":"8","author":"Ramadan N.M.","year":"2003","unstructured":"Ramadan N.M.; The link between glutamate and migraine. CNS Spectr  2003,8(6),446-449","journal-title":"CNS Spectr"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00213-005-2200-z","volume":"179","author":"Kew J.N.C.","year":"2005","unstructured":"Kew J.N.C.; Kemp J.A.; Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl)  2005,179(1),4-29","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/pr.109.002451","volume":"62","author":"Traynelis S.F.","year":"2010","unstructured":"Traynelis S.F.; Wollmuth L.P.; McBain C.J.; Menniti F.S.; Vance K.M.; Ogden K.K.; Hansen K.B.; Yuan H.; Myers S.J.; Dingledine R.; Glutamate receptor ion channels: Structure, regulation, and function. Pharmacol Rev  2010,62(3),405-496","journal-title":"Pharmacol Rev"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.3390\/cells11162608","volume":"11","author":"Mazzitelli M.","year":"2022","unstructured":"Mazzitelli M.; Presto P.; Antenucci N.; Meltan S.; Neugebauer V.; Recent advances in the modulation of pain by the metabotropic glutamate receptors. Cells  2022,11(16),2608","journal-title":"Cells"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.neuron.2018.05.018","volume":"98","author":"Reiner A.","year":"2018","unstructured":"Reiner A.; Levitz J.; Glutamatergic signaling in the central nervous system: Ionotropic and metabotropic receptors in concert. Neuron  2018,98(6),1080-1098","journal-title":"Neuron"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0304-3959(00)00478-4","volume":"89","author":"Burstein R.","year":"2001","unstructured":"Burstein R.; Deconstructing migraine headache into peripheral and central sensitization. Pain  2001,89(2),107-110","journal-title":"Pain"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1093\/brain\/123.8.1703","volume":"123","author":"Burstein R.","year":"2000","unstructured":"Burstein R.; Cutrer M.F.; Yarnitsky D.; The development of cutaneous allodynia during a migraine attack Clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain  2000,123(8),1703-1709","journal-title":"Brain"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N","volume":"47","author":"Burstein R.","year":"2000","unstructured":"Burstein R.; Yarnitsky D.; Goor-Aryeh I.; Ransil B.J.; Bajwa Z.H.; An association between migraine and cutaneous allodynia. Ann Neurol  2000,47(5),614-624","journal-title":"Ann Neurol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"6921","DOI":"10.1038\/s41598-022-10883-9","volume":"12","author":"Park C.G.","year":"2022","unstructured":"Park C.G.; Chu M.K.; Interictal plasma glutamate levels are elevated in individuals with episodic and chronic migraine. Sci Rep  2022,12(1),6921","journal-title":"Sci Rep"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1468-2982.2009.01881.x","volume":"30","author":"Baad-Hansen L.","year":"2010","unstructured":"Baad-Hansen L.; Cairns B.E.; Ernberg M.; Svensson P.; Effect of systemic monosodium glutamate (MSG) on headache and pericranial muscle sensitivity. Cephalalgia  2010,30(1),68-76","journal-title":"Cephalalgia"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1129-2377-14-2","volume":"14","author":"Shimada A.","year":"2013","unstructured":"Shimada A.; Cairns B.E.; Vad N.; Ulriksen K.; Pedersen A.M.L.; Svensson P.; Baad-Hansen L.; Headache and mechanical sensitization of human pericranial muscles after repeated intake of monosodium glutamate (MSG). J Headache Pain  2013,14(1),2","journal-title":"J Headache Pain"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.pain.2005.01.008","volume":"114","author":"Liang Y.C.","year":"2005","unstructured":"Liang Y.C.; Huang C.C.; Hsu K.S.; Characterization of long-term potentiation of primary afferent transmission at trigeminal synapses of juvenile rats: Essential role of subtype 5 metabotropic glutamate receptors. Pain  2005,114(3),417-428","journal-title":"Pain"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1212\/WNL.82.10_supplement.P1.25","volume":"82","author":"Hoffmann J.","year":"2014","unstructured":"Hoffmann J.; Martins-Oliveira M.; Supronsinchai W.; The CK1\u03b4 T44A mutation affects nociceptive activation of the trigeminocervical complex in an in vivo model of migraine (P1.258). Neurology  2014,82(10_supplement),258","journal-title":"Neurology"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcdb.2013.10.005","volume":"27","author":"Lad\u00e9p\u00eache L.","year":"2014","unstructured":"Lad\u00e9p\u00eache L.; Dupuis J.P.; Groc L.; Surface trafficking of NMDA receptors: Gathering from a partner to another. Semin Cell Dev Biol  2014,27,3-13","journal-title":"Semin Cell Dev Biol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/0166-2236(95)80016-U","volume":"18","author":"Collingridge G.L.","year":"1995","unstructured":"Collingridge G.L.; Bliss T.V.P.; Memories of NMDA receptors and LTP. Trends Neurosci  1995,18(2),54-56","journal-title":"Trends Neurosci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/0149-7634(95)00017-8","volume":"19","author":"Rison R.A.","year":"1995","unstructured":"Rison R.A.; Stanton P.K.; Long-term potentiation and N-methyl-d-aspartate receptors: Foundations of memory and neurologic disease? Neurosci Biobehav Rev  1995,19(4),533-552","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1080\/13543776.2020.1811234","volume":"30","author":"Ahmed H.","year":"2020","unstructured":"Ahmed H.; Haider A.; Ametamey S.M.; N -Methyl-D-Aspartate (NMDA) receptor modulators: A patent review (2015-present). Expert Opin Ther Pat  2020,30(10),743-767","journal-title":"Expert Opin Ther Pat"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0028-3908(99)00019-2","volume":"38","author":"Parsons C.G.","year":"1999","unstructured":"Parsons C.G.; Danysz W.; Quack G.; Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist\u2014a review of preclinical data. Neuropharmacology  1999,38(6),735-767","journal-title":"Neuropharmacology"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/j.1460-9568.2011.07628.x","volume":"33","author":"Paoletti P.","year":"2011","unstructured":"Paoletti P.; Molecular basis of NMDA receptor functional diversity. Eur J Neurosci  2011,33(8),1351-1365","journal-title":"Eur J Neurosci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.neuroscience.2016.08.007","volume":"334","author":"O\u2019Brien M.","year":"2016","unstructured":"O\u2019Brien M.; Cairns B.E.; Monosodium glutamate alters the response properties of rat trigeminovascular neurons through activation of peripheral NMDA receptors. Neuroscience  2016,334,236-244","journal-title":"Neuroscience"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.3390\/ijms23031529","volume":"23","author":"Guerrero-Toro C.","year":"2022","unstructured":"Guerrero-Toro C.; Koroleva K.; Ermakova E.; Ga furov O.; Abushik P.; Tavi P.; Sitdikova G.; Giniatullin R.; Testing the role of glutamate NMDA receptors in peripheral trigeminal nociception im plicated in migraine pain. Int J Mol Sci  2022,23(3),1529","journal-title":"Int J Mol Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejphar.2013.09.009","volume":"718","author":"Zhou Q.","year":"2013","unstructured":"Zhou Q.; Wang J.; Zhang X.; Zeng L.; Wang L.; Jiang W.; Effect of metabotropic glutamate 5 receptor antagonists on morphine efficacy and tolerance in rats with neuropathic pain. Eur J Pharmacol  2013,718(1-3),17-23","journal-title":"Eur J Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/archneur.65.6.709","volume":"65","author":"Rogawski M.A.","year":"2008","unstructured":"Rogawski M.A.; Common pathophysiologic mechanisms in migraine and epilepsy. Arch Neurol  2008,65(6),709-714","journal-title":"Arch Neurol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jpain.2009.06.012","volume":"10","author":"Latremoliere A.","year":"2009","unstructured":"Latremoliere A.; Woolf C.J.; Central sensitization: A generator of pain hypersensitivity by central neural plasticity. J Pain  2009,10(9),895-926","journal-title":"J Pain"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0304-3940(92)90339-9","volume":"141","author":"Tallaksen-Greene S.J.","year":"1992","unstructured":"Tallaksen-Greene S.J.; Young A.B.; Penney J.B.; Beitz A.J.; Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat. Neurosci Lett  1992,141(1),79-83","journal-title":"Neurosci Lett"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3390\/biomedicines11030686","volume":"11","author":"Huang T.H.","year":"2023","unstructured":"Huang T.H.; Lai M.C.; Chen Y.S.; Huang C.W.; The roles of glutamate receptors and their antagonists in status epilepticus, refractory status epilepticus, and super-refractory status epilepticus. Biomedicines  2023,11(3),686","journal-title":"Biomedicines"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s10194-022-01469-x","volume":"23","author":"Zhang W.","year":"2022","unstructured":"Zhang W.; Lei M.; Wen Q.; Zhang D.; Qin G.; Zhou J.; Chen L.; Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine. J Headache Pain  2022,23(1),98","journal-title":"J Headache Pain"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/epi.14082","volume":"59","author":"Leo A.","year":"2018","unstructured":"Leo A.; Giovannini G.; Russo E.; Meletti S.; The role of AMPA receptors and their antagonists in status epilepticus. Epilepsia  2018,59(6),1098-1108","journal-title":"Epilepsia"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"711564","DOI":"10.3389\/fncir.2021.711564","volume":"15","author":"Guo C.","year":"2021","unstructured":"Guo C.; Ma Y.Y.; Calcium permeable-AMPA receptors and excitotoxicity in neurological disorders. Front Neural Circuits  2021,15,711564","journal-title":"Front Neural Circuits"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.conb.2011.01.001","volume":"21","author":"Man H.Y.","year":"2011","unstructured":"Man H.Y.; GluA2-lacking, calcium-permeable AMPA receptors-inducers of plasticity?. Curr Opin Neurobiol  2011,21(2),291-298","journal-title":"Curr Opin Neurobiol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1067\/mcp.2000.108677","volume":"68","author":"Gilron I.","year":"2000","unstructured":"Gilron I.; Max M.B.; Lee G.; Booher S.L.; Sang C.N.; Chappell A.S.; Dionne R.A.; Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid\/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clin Pharmacol Ther  2000,68(3),320-327","journal-title":"Clin Pharmacol Ther"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/j.1476-5381.2010.00733.x","volume":"160","author":"Chan K.Y.","year":"2010","unstructured":"Chan K.Y.; Gupta S.; de Vries R.; Danser A.H.; Villal\u00f3n C.M.; Mu\u00f1oz-Islas E.; Maassenvanden brink, A. Effects of ionotropic glutamate receptor an tagonists on rat dural artery diameter in an intravital microscopy model. Br J Pharmacol  2010,160(6),1316-1325","journal-title":"Br J Pharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3390\/ijms24031908","volume":"24","author":"Cha\u0142upnik P.","year":"2023","unstructured":"Cha\u0142upnik P.; Szyma\u0144ska E.; Kainate receptor antagonists: Recent advances and therapeutic perspective. Int J Mol Sci  2023,24(3),1908","journal-title":"Int J Mol Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1124\/pharmrev.120.000131","volume":"73","author":"Hansen K.B.","year":"2021","unstructured":"Hansen K.B.; Wollmuth L.P.; Bowie D.; Furukawa H.; Menniti F.S.; Sobolevsky A.I.; Swanson G.T.; Swanger S.A.; Greger I.H.; Nakagawa T.; McBain C.J.; Jayaraman V.; Low C.M.; Dell\u2019Acqua M.L.; Diamond J.S.; Camp C.R.; Perszyk R.E.; Yuan H.; Traynelis S.F.; Structure, function, and pharmacology of glutamate receptor ion channels. Pharmacol Rev  2021,73(4),1469-1658","journal-title":"Pharmacol Rev"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0301-0082(03)00122-9","volume":"70","author":"Huettner J.E.","year":"2003","unstructured":"Huettner J.E.; Kainate receptors and synaptic transmission. Prog Neurobiol  2003,70(5),387-407","journal-title":"Prog Neurobiol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/00001756-199603220-00012","volume":"7","author":"Zhou S.","year":"1996","unstructured":"Zhou S.; Bonasera L.; Carlton S.M.; Peripheral administration of NMDA, AMPA or KA results in pain behaviors in rats. Neuroreport  1996,7(4),895-900","journal-title":"Neuroreport"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0014-2999(95)00449-U","volume":"284","author":"Jackson D.L.","year":"1995","unstructured":"Jackson D.L.; Graff C.B.; Richardson J.D.; Hargreaves K.M.; Glutamate participates in the peripheral modulation of thermal hyperalgesia in rats. Eur J Pharmacol  1995,284(3),321-325","journal-title":"Eur J Pharmacol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.semcdb.2006.10.008","volume":"17","author":"Bleakman D.","year":"2006","unstructured":"Bleakman D.; Alt A.; Nisenbaum E.S.; Glutamate receptors and pain. Semin Cell Dev Biol  2006,17(5),592-604","journal-title":"Semin Cell Dev Biol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0028-3908(00)00114-3","volume":"40","author":"Walker K.","year":"2001","unstructured":"Walker K.; Reeve A.; Bowes M.; Winter J.; Woth erspoon G.; Davis A.; Schmid P.; Gasparini F.; Kuhn R.; Urban L.; mGlu5 receptors and nocicep tive function II. mGlu5 receptors functionally ex pressed on peripheral sensory neurones mediate in flammatory hyperalgesia. Neuropharmacology  2001,40(1),10-19","journal-title":"Neuropharmacology"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0028-3908(00)00113-1","volume":"40","author":"Walker K.","year":"2001","unstructured":"Walker K.; Bowes M.; Panesar M.; Davis A.; Metabotropic glutamate receptor sub type 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, per sistent and chronic pain. Neuropharmacology  2001,40(1),1-9","journal-title":"Neuropharmacology"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/acn3.302","volume":"3","author":"Waung M.W.","year":"2016","unstructured":"Waung M.W.; Akerman S.; Wakefield M.; Keywood C.; Goadsby P.J.; Metabotropic glutamate receptor 5: A target for migraine therapy. Ann Clin Transl Neurol  2016,3(8),560-571","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/bph.15640","volume":"179","author":"Copeland C.S.","year":"2022","unstructured":"Copeland C.S.; Neale S.A.; Nisenbaum E.S.; Salt T.E.; Group II metabotropic glutamate receptor (MGLU 2 and MGLU 3) roles in thalamic processing. Br J Pharmacol  2022,179(8),1607-1619","journal-title":"Br J Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0304-3959(95)00095-X","volume":"64","author":"Bereiter D.A.","year":"1996","unstructured":"Bereiter D.A.; Bereiter D.F.; Hathaway C.B.; The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity in central trigeminal neurons and blocks select endocrine and autonomic responses to corneal stimulation in the rat. Pain  1996,64(1),179-189","journal-title":"Pain"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0006-8993(01)02550-1","volume":"907","author":"Classey J.D.","year":"2001","unstructured":"Classey J.D.; Knight Y.E.; Goadsby P.J.; The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat. Brain Res  2001,907(1-2),117-124","journal-title":"Brain Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.brainres.2004.06.048","volume":"1021","author":"Hattori Y.","year":"2004","unstructured":"Hattori Y.; Watanabe M.; Iwabe T.; Tanaka E.; Nishi M.; Aoyama J.; Satoda T.; Uchida T.; Tanne K.; Administration of MK-801 decreases c-Fos expression in the trigeminal sensory nuclear complex but increases it in the midbrain during experimental movement of rat molars. Brain Res  2004,1021(2),183-191","journal-title":"Brain Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0304-3959(98)00051-7","volume":"76","author":"Mitsikostas D.D.","year":"1998","unstructured":"Mitsikostas D.D.; del Rio M.S.; Waeber C.; Moskowitz M.A.; Cutrer M.F.; The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain  1998,76(1),239-248","journal-title":"Pain"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3390\/ijms18081617","volume":"18","author":"Nagy-Gr\u00f3cz G.","year":"2017","unstructured":"Nagy-Gr\u00f3cz G.; Z\u00e1dor F.; Dvor\u00e1csk\u00f3 S.; Boh\u00e1r Z.; Benyhe S.; T\u00f6mb\u00f6ly C.; P\u00e1rdutz \u00c1.; V\u00e9csei L.; Interactions between the kynurenine and the endocannabinoid system with special emphasis on migraine. Int J Mol Sci  2017,18(8),1617","journal-title":"Int J Mol Sci"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"664","DOI":"10.2174\/1871527314666150429114040","volume":"14","author":"V\u00e9csei L.","year":"2015","unstructured":"V\u00e9csei L.; Majl\u00e1th Z.; Balog A.; Tajti J.; Drug targets of migraine and neuropathy: Treatment of hyperexcitability. CNS Neurol Disord Drug Targets  2015,14(5),664-676","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1177\/0333102411404717","volume":"31","author":"Guo S.","year":"2011","unstructured":"Guo S.; Vecsei L.; Ashina M.; The L-kynurenine signalling pathway in trigeminal pain processing: A potential therapeutic target in migraine? Cephalalgia  2011,31(9),1029-1038","journal-title":"Cephalalgia"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"e00741","DOI":"10.1002\/prp2.741","volume":"9","author":"Al-Karagholi M.A.M.","year":"2021","unstructured":"Al-Karagholi M.A.M.; Hansen J.M.; Abou-Kassem D.; Hansted A.K.; Ubhayasekera K.; Bergquist J.; V\u00e9csei L.; Jansen-Olesen I.; Ashina M.; Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers. Pharmacol Res Perspect  2021,9(2),e00741","journal-title":"Pharmacol Res Perspect"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0014-2999(88)90367-6","volume":"154","author":"Birch P.J.","year":"1988","unstructured":"Birch P.J.; Grossman C.J.; Hayes A.G.; Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol  1988,154(1),85-87","journal-title":"Eur J Pharmacol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/j.1471-4159.1991.tb03460.x","volume":"56","author":"Fukui S.","year":"1991","unstructured":"Fukui S.; Schwarcz R.; Rapoport S.I.; Takada Y.; Smith Q.R.; Blood-brain barrier transport of kynurenines: Implications for brain synthesis and metabolism. J Neurochem  1991,56(6),2007-2017","journal-title":"J Neurochem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3389\/fneur.2019.00778","volume":"10","author":"Colpo G.D.","year":"2019","unstructured":"Colpo G.D.; Venna V.R.; McCullough L.D.; Teixeira A.L.; Systematic review on the involvement of the kynurenine pathway in stroke: Pre-clinical and clinical evidence. Front Neurol  2019,10,778","journal-title":"Front Neurol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0014-2999(91)90436-T","volume":"196","author":"V\u00e9csei L.","year":"1991","unstructured":"V\u00e9csei L.; Beal M.F.; Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats. Eur J Pharmacol  1991,196(3),239-246","journal-title":"Eur J Pharmacol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/0333102413499648","volume":"34","author":"Gomez-Mancilla B.","year":"2014","unstructured":"Gomez-Mancilla B.; Brand R.; Jurgens T.P.; Gobel H.; Sommer C.; Straube A.; Evers S.; Sommer M.; Campos V.; Kalkman H.O.; Hariry S.; Pezous N.; Johns D.; Diener H-C.; Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia  2014,34(2),103-113","journal-title":"Cephalalgia"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/0333102413499646","volume":"34","author":"Ramadan N.M.","year":"2014","unstructured":"Ramadan N.M.; Glutamate and migraine: From Ikeda to the 21st century. Cephalalgia  2014,34(2),86-89","journal-title":"Cephalalgia"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"6611","DOI":"10.1523\/JNEUROSCI.17-17-06611.1997","volume":"17","author":"Sahara Y.","year":"1997","unstructured":"Sahara Y.; Noro N.; Iida Y.; Soma K.; Nakamura Y.; Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons. J Neurosci  1997,17(17),6611-6620","journal-title":"J Neurosci"},{"key":"ref=74","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199552764.003.0022","author":"Johnson K.W.","year":"2008","unstructured":"Johnson K.W.; Nisenbaum E.S.; Johnson M.P.; Dieckman D.K.; Clemens-Smith A.; Siuda E.R.; In novative drug development for headache disorders: glutamate. Frontiers in Headache Research Series  2008","journal-title":"Frontiers in Headache Research Series"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/01.j.pain.0000460325.25762.c0","volume":"156","author":"Andreou A.P.","year":"2015","unstructured":"Andreou A.P.; Holland P.R.; Lasalandra M.P.; Goadsby P.J.; Modulation of nociceptive dural input to the trigeminocervical complex through GluK1 kainate receptors. Pain  2015,156(3),439-450","journal-title":"Pain"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1476-5381.2009.00142.x","volume":"157","author":"Andreou A.P.","year":"2009","unstructured":"Andreou A.P.; Holland P.R.; Goadsby P.J.; Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation. Br J Pharmacol  2009,157(3),464-473","journal-title":"Br J Pharmacol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1468-2982.2004.00723.x","volume":"24","author":"Sang C.N.","year":"2004","unstructured":"Sang C.N.; Ramadan N.M.; Wallihan R.G.; Chappell A.S.; Freitag F.G.; Smith T.R.; Silberstein S.D.; Johnson K.W.; Phebus L.A.; Bleakman D.; Ornstein P.L.; Arnold B.; Tepper S.J.; Vandenhende F.; LY293558, a novel AMPA\/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia  2004,24(7),596-602","journal-title":"Cephalalgia"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"173446","DOI":"10.1016\/j.pbb.2022.173446","volume":"219","author":"Witkin J.M.","year":"2022","unstructured":"Witkin J.M.; Pandey K.P.; Smith J.L.; Clinical investigations of compounds targeting metabotropic glutamate receptors. Pharmacol Biochem Behav  2022,219,173446","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1517\/13543781003691832","volume":"19","author":"Marin J.C.A.","year":"2010","unstructured":"Marin J.C.A.; Goadsby P.J.; Glutamatergic fine tuning with ADX-10059: A novel therapeutic approach for migraine? Expert Opin Investig Drugs  2010,19(4),555-561","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3892\/etm.2020.8802","volume":"20","author":"Terzioglu B.","year":"2020","unstructured":"Terzioglu B.; Oguz E.; Acet G.; Effect of valproic acid on oxidative stress parameters of glutamate induced excitotoxicity in SH SY5Y cells. Exp Ther Med  2020,20(2),1321-1328","journal-title":"Exp Ther Med"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.neuroscience.2012.08.060","volume":"225","author":"Chaudhary S.","year":"2012","unstructured":"Chaudhary S.; Parvez S.; An in vitro approach to assess the neurotoxicity of valproic acid-induced oxidative stress in cerebellum and cerebral cortex of young rats. Neuroscience  2012,225,258-268","journal-title":"Neuroscience"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12264-010-0813-7","volume":"26","author":"Sun Z.W.","year":"2010","unstructured":"Sun Z.W.; Zhang L.; Zhu S.J.; Chen W.C.; Mei B.; Excitotoxicity effects of glutamate on human neuroblastoma SH-SY5Y cells via oxidative damage. Neurosci Bull  2010,26(1),8-16","journal-title":"Neurosci Bull"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1089\/neu.2013.3146","volume":"31","author":"Lee J.Y.","year":"2014","unstructured":"Lee J.Y.; Maeng S.; Kang S.R.; Choi H.Y.; Oh T.H.; Ju B.G.; Yune T.Y.; Valproic acid protects motor neuron death by inhibiting oxidative stress and endoplasmic reticulum stress-mediated cytochrome C release after spinal cord injury. J Neurotrauma  2014,31(6),582-594","journal-title":"J Neurotrauma"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00415-004-0464-6","volume":"251","author":"Diener H.C.","year":"2004","unstructured":"Diener H.C.; Tfelt-Hansen P.; Dahl\u00f6f C.; L\u00e1inez M.J.; Sandrini G.; Wang S.J.; Neto W.; Vijapurkar U.; Doyle A.; Jacobs D.; Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control. J Neurol  2004,251(8),943-950","journal-title":"J Neurol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1528-1157.2000.tb02173.x","volume":"41","author":"Zhang X.","year":"2000","unstructured":"Zhang X.; Velumian A.A.; Jones O.T.; Carlen P.L.; Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia  2000,41(S1),52-60","journal-title":"Epilepsia"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0022-3565(24)38047-4","volume":"288","author":"Taverna S.","year":"1999","unstructured":"Taverna S.; Sancini G.; Mantegazza M.; Frances chetti S.; Avanzini G.; Inhibition of transient and persistent Na+ current fractions by the new anti covulsant topiramate. J Pharmacol Exp Ther  1999,288(3),960-968","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/s0920-1211(97)00045-4","volume":"28","author":"White H.S.","year":"1997","unstructured":"White H.S.; Brown S.D.; Woodhead J.H.; Skeen G.A.; Wolf H.H.; Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res  1997,28(3),167-179","journal-title":"Epilepsy Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.neuropharm.2004.02.010","volume":"46","author":"Kaminski R.M.","year":"2004","unstructured":"Kaminski R.M.; Banerjee M.; Rogawski M.A.; Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology  2004,46(8),1097-1104","journal-title":"Neuropharmacology"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13311-018-0621-8","volume":"15","author":"Sprenger T.","year":"2018","unstructured":"Sprenger T.; Viana M.; Tassorelli C.; Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics  2018,15(2),313-323","journal-title":"Neurotherapeutics"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1046\/j.1468-2982.1997.1702109.x","volume":"17","author":"Steiner T.J.","year":"1997","unstructured":"Steiner T.J.; Findley L.J.; Yuen A.W.C.; Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia  1997,17(2),109-112","journal-title":"Cephalalgia"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1468-2982.1999.1901058.x","volume":"19","author":"Lampl C.","year":"1999","unstructured":"Lampl C.; Buzath A.; Klinger D.; Neumann K.; Lamotrigine in the prophylactic treatment of migraine aura-a pilot study. Cephalalgia  1999,19(1),58-63","journal-title":"Cephalalgia"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1468-2982.1999.1901064.x","volume":"19","author":"D\u2019Andrea G.","year":"1999","unstructured":"D\u2019Andrea G.; Granella F.; Cadaldini M.; Manzoni G.C.; Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia  1999,19(1),64-66","journal-title":"Cephalalgia"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-019-1046-4","volume":"20","author":"Hansen J.M.","year":"2019","unstructured":"Hansen J.M.; Charles A.; Differences in treatment response between migraine with aura and migraine without aura: Lessons from clinical practice and RCTs. J Headache Pain  2019,20(1),96","journal-title":"J Headache Pain"},{"key":"ref=94","first-page":"E285","volume":"20","author":"Iacobucci G.J.","year":"2017","unstructured":"Iacobucci G.J.; Visnjevac O.; Pourafkari L.; Nader N.D.; Ketamine: An update on cellular and subcellular mechanisms with implications for clinical practice. Pain Physician  2017,20(2),E285-E301","journal-title":"Pain Physician"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"e27389","DOI":"10.7759\/cureus.27389","volume":"14","author":"Rueda Carrillo L.","year":"2022","unstructured":"Rueda Carrillo L.; Garcia K.A.; Yalcin N.; Shah M.; Ketamine and its emergence in the field of neurology. Cureus  2022,14(7),e27389","journal-title":"Cureus"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"952","DOI":"10.5811\/westjem.2018.8.37875","volume":"19","author":"Etchison A.","year":"2018","unstructured":"Etchison A.; Bos L.; Ray M.; McAllister K.; Mohammed M.; Park B.; Phan A.; Heitz C.; Low-dose ketamine does not improve migraine in the emergency department: A randomized placebo-controlled trial. West J Emerg Med  2018,19(6),952-960","journal-title":"West J Emerg Med"},{"key":"ref=97","first-page":"181","volume":"15","author":"Nicolodi M.","year":"1995","unstructured":"Nicolodi M.; Sicuteri F.; Exploration of NMDA receptors in migraine: Therapeutic and theoretic implications. Int J Clin Pharmacol Res  1995,15(5-6),181-189","journal-title":"Int J Clin Pharmacol Res"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/1570159x14666160309114549","volume":"15","author":"Wohleb E.S.","year":"2017","unstructured":"Wohleb E.S.; Gerhard D.; Thomas A.; Duman R.S.; Molecular and cellular mechanisms of rapid-acting antidepressants ketamine and scopolamine. Curr Neuropharmacol  2017,15(1),11-20","journal-title":"Curr Neuropharmacol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0304-3940(01)01872-9","volume":"306","author":"Rammes G.","year":"2001","unstructured":"Rammes G.; Rupprecht R.; Ferrari U.; Zieglg\u00e4nsberger W.; Parsons C.G.; The N-methyl-d-aspartate receptor channel blockers memantine, MRZ 2\/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett  2001,306(1-2),81-84","journal-title":"Neurosci Lett"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.2174\/1381612825666191011102444","volume":"25","author":"Kabir M.T.","year":"2019","unstructured":"Kabir M.T.; Sufian M.A.; Uddin M.S.; Begum M.M.; Akhter S.; Islam A.; Mathew B.; Islam M.S.; Amran M.S.; Md Ashraf G.; NMDA receptor antagonists: Repositioning of memantine as a multitargeting agent for Alzheimer\u2019s therapy. Curr Pharm Des  2019,25(33),3506-3518","journal-title":"Curr Pharm Des"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/head.14186","volume":"61","author":"Mistry V.M.","year":"2021","unstructured":"Mistry V.M.; Morizio P.L.; Pepin M.J.; Bryan W.E.; Brown J.N.; Role of memantine in the prophylactic treatment of episodic migraine: A systematic review. Headache  2021,61(8),1207-1213","journal-title":"Headache"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"286","DOI":"10.4103\/aian.AIAN_294_18","volume":"22","author":"Shanmugam S.","year":"2019","unstructured":"Shanmugam S.; Karunaikadal K.; Varadarajan S.; Krishnan M.; Memantine ameliorates migraine headache. Ann Indian Acad Neurol  2019,22(3),286-290","journal-title":"Ann Indian Acad Neurol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/j.1526-4610.2008.01083.x","volume":"48","author":"Bigal M.","year":"2008","unstructured":"Bigal M.; Rapoport A.; Sheftell F.; Tepper D.; Tepper S.; Memantine in the preventive treatment of refractory migraine. Headache  2008,48(9),1337-1342","journal-title":"Headache"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1080\/14656566.2022.2102420","volume":"23","author":"Bentivegna E.","year":"2022","unstructured":"Bentivegna E.; Luciani M.; Ferrari V.; Galastri S.; Baldari F.; Scarso F.; Lamberti P.A.; Martelletti P.; Recently approved and emerging drug options for migraine prophylaxis. Expert Opin Pharmacother  2022,23(11),1325-1335","journal-title":"Expert Opin Pharmacother"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/WNF.0000000000000504","volume":"45","author":"Zhou T.","year":"2022","unstructured":"Zhou T.; Tang Y.; Zhu H.; Effectiveness and safety of memantine for headache: A meta-analysis of randomized controlled studies. Clin Neuropharmacol  2022,45(3),40-44","journal-title":"Clin Neuropharmacol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3390\/nu14051089","volume":"14","author":"Domitrz I.","year":"2022","unstructured":"Domitrz I.; Cegielska J.; Magnesium as an important factor in the pathogenesis and treatment of migraine\u2014from theory to practice. Nutrients  2022,14(5),1089","journal-title":"Nutrients"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.3390\/nu12082184","volume":"12","author":"Shin H.J.","year":"2020","unstructured":"Shin H.J.; Na H.S.; Do S.H.; Magnesium and Pain. Nutrients  2020,12(8),2184","journal-title":"Nutrients"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/medsci7040056","volume":"7","author":"Ahmed F.","year":"2019","unstructured":"Ahmed F.; Mohammed A.; Magnesium: The forgotten electrolyte\u2014a review on hypomagnesemia. Med Sci (Basel)  2019,7(4),56","journal-title":"Med Sci (Basel)"},{"key":"ref=109","first-page":"153","volume":"19","author":"Arpaci D.","year":"2015","unstructured":"Arpaci D.; Tocoglu A.G.; Ergenc H.; Korkmaz S.; Ucar A.; Tamer A.; Associations of serum Magnesium levels with diabetes mellitus and diabetic complications. Hippokratia  2015,19(2),153-157","journal-title":"Hippokratia"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"e00063","DOI":"10.1002\/prp2.63","volume":"2","author":"Hanada T.","year":"2014","unstructured":"Hanada T.; Ido K.; Kosasa T.; Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model. Pharmacol Res Perspect  2014,2(5),e00063","journal-title":"Pharmacol Res Perspect"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"108391","DOI":"10.1016\/j.yebeh.2021.108391","volume":"125","author":"Fernandes M.","year":"2021","unstructured":"Fernandes M.; Dono F.; Dainese F.; Renna R.; Consoli S.; Gaspari C.; Izzi F.; Pagliuca M.; Placidi F.; Biagio Mercuri N.; Liguori C.; Perampanel may represent an effective treatment for the preven tion of migraine comorbid with epilepsy. Epilepsy Behav  2021,125,108391","journal-title":"Epilepsy Behav"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1007\/s00415-021-10506-9","volume":"268","author":"Lim S.N.","year":"2021","unstructured":"Lim S.N.; Wu T.; Tseng W.E.J.; Chiang H.I.; Cheng M.Y.; Lin W.R.; Lin C.N.; Efficacy and safety of perampanel in refractory and super-refractory status epilepticus: cohort study of 81 patients and literature review. J Neurol  2021,268(10),3744-3757","journal-title":"J Neurol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/epi.12504","volume":"55","author":"Rugg-Gunn F.","year":"2014","unstructured":"Rugg-Gunn F.; Adverse effects and safety profile of perampanel: A review of pooled data. Epilepsia  2014,55(s1),13-15","journal-title":"Epilepsia"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X23666250403124115","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/240698\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X23666250403124115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T06:27:05Z","timestamp":1752560825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/240698\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":113,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x23666250403124115","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}